Presentation is loading. Please wait.

Presentation is loading. Please wait.

BSRBR-RA UK CRN ID: 7302 July 2014 update. Recruitment Certolizumab Must have diagnosis of RA Must be registered within 6 months of first dose of certolizumab.

Similar presentations


Presentation on theme: "BSRBR-RA UK CRN ID: 7302 July 2014 update. Recruitment Certolizumab Must have diagnosis of RA Must be registered within 6 months of first dose of certolizumab."— Presentation transcript:

1 BSRBR-RA UK CRN ID: 7302 July 2014 update

2 Recruitment Certolizumab Must have diagnosis of RA Must be registered within 6 months of first dose of certolizumab Can be re-registered if already on the study Tocilizumab Must have diagnosis of RA Must be registered within 6 months of first dose of IV or S/C tocilizumab Can be re-registered if already on the study Anti-TNF Comparison Cohort Must have diagnosis of RA Must be registered within 6 months of first dose of etanercept, adalimumab or infliximab Numbers recruited up to 30/06/ As of 30/06/ As of 30/06/ As of 30/06/2014

3 Recruitment over the last year Certolizumab recruitment by month (1 July 2013 – 30 June 2014) Tocilizumab recruitment by month (1 July 2013 – 30 June 2014) Anti-TNF cohort recruitment by month (1 July 2013 – 30 June 2014)

4 Recruitment 01/01/2014 – 30/06/2014

5 BSR Region Awards January 2014 – July 2014 North West East of England West Midlands East Midlands

6 Recent BSRBR-RA publications – Risk of solid cancer in patients exposed to anti-TNF therapy: results from the BSRBR-RA. Mercer, L., Lunt, M., Low, A., Dixon, W., Watson, K., Symmons, D. &Hyrich, K (2014). Ann Rheum Dis, [Epub ahead of print] -Biologic treatment response among adults with juvenile idiopathic arthritis: results from the British Society for Rheumatology Biologics Register. McErlane F, Foster HE, Davies R, Lunt M, Watson KD, Symmons DP, Hyrich KL. (2013) Rheumatology (Oxford), [Epub ahead of print] – The risk of gastrointestinal perforations in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the BSRBR-RA. Závada, J., Lunt, M., Davies, R., Low, A., Mercer, L., Galloway, J., Watson, K., Symmons, D., Hyrich, K. & (2013). Ann Rheum Dis, [Epub ahead of print]

7 Accessing BSRBR-RA data You can access data from the BSRBR-RA via a “third party data request form” (contact for a copy). Proposals should be discussed with in advance of submission to discuss feasibility. Proposals can be submitted at any time of the year – there are no submission deadlines.

8 Recent/ongoing research projects via the BSRBR-RA data access scheme  Non-inflammatory pain mechanisms as confounders in the clinical assessment of synovitis in RA  Study of fatigue in inflammatory arthritis  Effectiveness of TNF response define by season of initiation of therapy, with particular focus on vitamin D  To explore the influence of gender and gender-related variables on severity of prognosis for RA  Obesity and clinical response to anti-TNF medication

9 Contacts Tel: /7390 Web:

10 Acknowledgements UK Consultant Rheumatologists and Specialist Nurses UK Comprehensive Research Networks BSRBR-RA Control Centre Consortium British Society for Rheumatology Arthritis Research UK Centre for Epidemiology, Manchester


Download ppt "BSRBR-RA UK CRN ID: 7302 July 2014 update. Recruitment Certolizumab Must have diagnosis of RA Must be registered within 6 months of first dose of certolizumab."

Similar presentations


Ads by Google